Cancer Drug Resistance
All Journals
Search Log In
Editor-in-Chief: Godefridus J. Peters
Indexing: ESCI, PMC, Scopus, CAS, CNKI, Dimensions, Lens, Embase,
Journal Rank: Impact Factor 2024: 5.2 - Q1 (ONCOLOGY); CiteScore 2024: 8.3 - Q1 [Pharmacology(medical)]
Median time to first editorial decision: 9 days
Home Articles Special Topics Volumes Webinars Videos
Cancer Drug Resistance
Search Submit
Editor-in-Chief: Godefridus J. Peters
Journal Rank: Impact Factor 2024: 5.2 - Q1 (ONCOLOGY); CiteScore 2024: 8.3 - Q1 [Pharmacology(medical)]
Median time to first editorial decision: 9 days
Home Articles Special Topics Volumes Webinars Videos

Cancer Drug Resistance

Mitochondria in colorectal cancer stem cells - a target in drug resistance

Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinoma

P-glycoprotein (ABCB1) - weak dipolar interactions provide the key to understanding allocrite recognition, binding, and transport

Heterotypic signaling of cancer-associated fibroblasts in shaping the cancer cell drug resistance

Targeting regulated cell death pathways in acute myeloid leukemia

Interview with Professor David A. Gewirtz: Exploring Breakthroughs in Cancer Drug Resistance and Treatment [Embedded Auto-Generated Subtitles]

NaN

Articles

Most Recent | Most Viewed | Most Downloaded

CDK4/6 and BET inhibitors synergistically suppress pancreatic tumor growth and epithelial-to-mesenchymal transition by regulating the GSK3β-mediated Wnt/β-catenin pathway

Jiangning Gu, ...Jianqiang Xu
Open Access Original Article DOI: 10.20517/cdr.2025.38 25 Sep 2025
Views: Downloads:
Download PDF

Cisplatin resistance in head and neck squamous cell carcinoma is linked to DNA damage response and cell cycle arrest transcriptomics rather than poor drug uptake

Ketaki Sandu, ...Dirk Theile
Open Access Original Article DOI: 10.20517/cdr.2025.107 18 Sep 2025
Views: Downloads:
Download PDF

Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitors

Cristina Corno, ...Paola Perego
Open Access Original Article DOI: 10.20517/cdr.2025.88 17 Sep 2025
Views: Downloads:
Download PDF

Distinct adaptive strategies to cisplatin, vinblastine and gemcitabine in a panel of chemoresistant bladder cancer cell lines

Monika Cuprych-Belter, ...Mateusz Psurski
Open Access Original Article DOI: 10.20517/cdr.2025.95 11 Sep 2025
Views: Downloads:
Download PDF

Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies

Yutao Chen, ...Hua Li
Open Access Review DOI: 10.20517/cdr.2025.120 10 Sep 2025
Views: Downloads:
Download PDF

Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system

Xiangyu Sun, ... Jianliang Shen
Open Access Review DOI: 10.20517/cdr.2023.16 19 Jun 2023
Views: Downloads:
Download PDF

Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects

William H. Gmeiner, Charles Chidi Okechukwu
Open Access Review DOI: 10.20517/cdr.2022.136 28 Apr 2023
Views: Downloads:
Download PDF

Anti-BCMA novel therapies for multiple myeloma

Vincenzo SammartanoVincenzo Sammartano, ... Alessandro GozzettiAlessandro Gozzetti
Open Access Review DOI: 10.20517/cdr.2022.138 21 Mar 2023
Views: Downloads:
Download PDF

Deciphering Therapeutic Resistance in Urological Cancers: Bridging Clonal Evolution, Microenvironment, and Multi-Omics for Clinical Translation

Dr. William Chi Shing Chi-Shing Cho; Dr. Dechao Feng; Dr. Umber Cheema

Submission Deadline: 30 Apr 2026

Published articles: 0

Tumor Biochemistry Meets Drug Resistance: Turning Molecular Weaknesses into Therapeutic Opportunities

Prof. Chiara Riganti; Dr. Joanna Kopecka; Dr. Iris Chiara Salaroglio

Submission Deadline: 19 Feb 2026

Published articles: 0

Coming soon.

For Reviewers

Peer Review Guidelines
For Readers

Add your e-mail address to receive forthcoming Issues of this journal:

Themed Collections
Resistance
Drug delivery
Nanomedicine
Tumor microenvironment
Immune checkpoint inhibitors
Target therapy
Immunotherapy
Radiotherapy
Ferroptosis
PARP inhibitors
MYC
ABC transporters
Autophagy
Metabolism
Mechanisms
Precision medicine
Extracellular vesicles
Stem cell
Biomarker
Ovarian cancer
Renal cell carcinoma
Prostate cancer
Breast cancer
Colorectal cancer
Myeloid leukemia
Non-small cell lung cancer
Pancreatic cancer
Head and neck cancer
Squamous cell carcinoma
Mitochondria
Topic: Ferroptosis, Cuproptosis, and Drug Resistance Research in Cancer
Topic: Papers from the Meeting of the European Organization of Research and Treatment of Cancer (EORTC) - Pharmacology and Molecular Mechanisms (PAMM) Group
Topic: Tackling the Challenge of Drug Resistance in Lung Cancer
Volume 8 (in progress)
Volume 7
Volume 6, Issue 4
Volume 6, Issue 3
Volume 6, Issue 2
Volume 6, Issue 1
Volume 5, Issue 4
Volume 5, Issue 3
Volume 5, Issue 2
Volume 5, Issue 1
Volume 4, Issue 4
Volume 4, Issue 3
Volume 4, Issue 2
Volume 4, Issue 1
Volume 3, Issue 4
Volume 3, Issue 3
Volume 3, Issue 2
Volume 3, Issue 1
Volume 2, Issue 4
Volume 2, Issue 3
Volume 2, Issue 2
Volume 2, Issue 1
Volume 1, Issue 4
Volume 1, Issue 3
Volume 1, Issue 2
Volume 1, Issue 1
Articles Collection
The Special Collection "Cancer Cell Plasticity in Therapy Resistance" Officially Launched and Open for Submissions
52 Editorial Board Members of Cancer Drug Resistance Recognized in the “World’s Top 2% Scientists 2025” List
Prestigious Honor, Global Impact: 52 CDR Editorial Board Members Ranked Among World's Top 2% Scientists, Reinforcing the Journal's Leadership in the Field
Celebrate OAE’s 10th Anniversary with Cancer Drug Resistance – Enjoy a $400 APC Discount!
Advancing the Fight Against Cancer Drug Resistance Together: Share Your Findings and Enjoy Anniversary Savings！
Cancer Drug Resistance Reaches New Heights with 2024 Impact Factor of 5.2
Marking a 13% rise, CDR continues to lead the field of cancer drug resistance.
Cancer Drug Resistance Reaches New Heights with 2024 CiteScore™ of 8.3
This marks a notable 25.8% increase from last year’s score of 6.6, underscoring the CDR’s rising academic impact and global recognition.
International Pancreatic Cancer Scientist Prof. Baiyong Shen Joins Cancer Drug Resistance as Associate Editor
We are thrilled to announce that Prof. Baiyong Shen, a globally recognized leader in pancreatic cancer research and Vice President of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, has officially joined Cancer Drug Resistance as an Associate Editor.

Mitochondria in colorectal cancer stem cells - a target in drug resistance

Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinoma

P-glycoprotein (ABCB1) - weak dipolar interactions provide the key to understanding allocrite recognition, binding, and transport

Heterotypic signaling of cancer-associated fibroblasts in shaping the cancer cell drug resistance

Targeting regulated cell death pathways in acute myeloid leukemia

Interview with Professor David A. Gewirtz: Exploring Breakthroughs in Cancer Drug Resistance and Treatment [Embedded Auto-Generated Subtitles]

NaN
Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
Xiangyu Sun, ... Jianliang Shen
Open Access | Review | 19 Jun 2023
Views: | Downloads:
Download PDF
Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects
William H. Gmeiner, Charles Chidi Okechukwu
Open Access | Review | 28 Apr 2023
Views: | Downloads:
Download PDF
Anti-BCMA novel therapies for multiple myeloma
Vincenzo SammartanoVincenzo Sammartano, ... Alessandro GozzettiAlessandro Gozzetti
Open Access | Review | 21 Mar 2023
Views: | Downloads:
Download PDF

Deciphering Therapeutic Resistance in Urological Cancers: Bridging Clonal Evolution, Microenvironment, and Multi-Omics for Clinical Translation

Dr. William Chi Shing Chi-Shing Cho; Dr. Dechao Feng; Dr. Umber Cheema

Submission Deadline: 30 Apr 2026

Published articles: 0

Tumor Biochemistry Meets Drug Resistance: Turning Molecular Weaknesses into Therapeutic Opportunities

Prof. Chiara Riganti; Dr. Joanna Kopecka; Dr. Iris Chiara Salaroglio

Submission Deadline: 19 Feb 2026

Published articles: 0

Coming soon.

Volume 8 (in progress)
Volume 7
Volume 6, Issue 4
Volume 6, Issue 3
Volume 6, Issue 2
Volume 6, Issue 1
Volume 5, Issue 4
Volume 5, Issue 3
Volume 5, Issue 2
Volume 5, Issue 1
Volume 4, Issue 4
Volume 4, Issue 3
Volume 4, Issue 2
Volume 4, Issue 1
Volume 3, Issue 4
Volume 3, Issue 3
Volume 3, Issue 2
Volume 3, Issue 1
Volume 2, Issue 4
Volume 2, Issue 3
Volume 2, Issue 2
Volume 2, Issue 1
Volume 1, Issue 4
Volume 1, Issue 3
Volume 1, Issue 2
Volume 1, Issue 1
Articles Collection
Cancer Drug Resistance
ISSN 2578-532X (Online)
Navigation
Follow Us
Navigation

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/
Discover Content
Follow OAE
Twitter
Facebook
LinkedIn
YouTube
BiLiBiLi
WeChat
Rss
© 2016-2025 OAE Publishing Inc., except certain content provided by third parties